Beneficial immunomodulatory and neuro digestive effect in Trypanosoma cruzi infection after Lycopodium clavatum 13c treatment

Aleixo, Camila Fernanda Brustolin; Ferraz, Fabiana Nabarro; Massini, Paula Fernanda; Lopes, Claudivan Sanches; Temporini, Gislaine Janaina Falkowski; Aleixo, Denise Lessa; Araújo, Silvana Márques de

doi:10.1016/j.micpath.2017.09.026

Cited by 11 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results, proving the antioxidant potential of Lyc, are in line with a previous study of a Lyc-enhanced antioxidant response in aging mice [42]. Lyc has also been reported to protect against cognitive [43], inflammatory [24,25] and neuronal [36,42] damage.…”

Section: Discussionsupporting

confidence: 92%

“…It has been a popular remedy in traditional Chinese and homeopathic medicines for centuries [18,19,20]. It has also been reported to possess anti-cancer [21,22], analgesic [23] and anti-inflammatory [24,25,26] properties. Lycopodium alkaloids, such as quinolizine or pyridine and α-pyridone-types, have been reported to possess acetylcholinesterase inhibition activity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson’s Disease

et al. 2019

View full text Add to dashboard Cite

Parkinson’s disease, a chronic, age related neurodegenerative disorder, is characterized by a progressive loss of nigrostriatal dopaminergic neurons. Several studies have proven that the activation of glial cells, presence of alpha-synuclein aggregates, and oxidative stress, fuels neurodegeneration, and currently there is no definitive treatment for PD. In this study, a rotenone-induced rat model of PD was used to understand the neuroprotective potential of Lycopodium (Lyc), a commonly-used potent herbal medicine. Immunohistochemcial data showed that rotenone injections significantly increased the loss of dopaminergic neurons in the substantia nigra, and decreased the striatal expression of tyrosine hydroxylase. Further, rotenone administration activated microglia and astroglia, which in turn upregulated the expression of α-synuclein, pro-inflammatory, and oxidative stress factors, resulting in PD pathology. However, rotenone-injected rats that were orally treated with lycopodium (50 mg/kg) were protected against dopaminergic neuronal loss by diminishing the expression of matrix metalloproteinase-3 (MMP-3) and MMP-9, as well as reduced activation of microglia and astrocytes. This neuroprotective mechanism not only involves reduction in pro-inflammatory response and α-synuclein expression, but also synergistically enhanced antioxidant defense system by virtue of the drug’s multimodal action. These findings suggest that Lyc has the potential to be further developed as a therapeutic candidate for PD.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson’s Disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Extracts from Lycopodium clavatum , a spore bearing vascular plant, act as an immuno-modulator to induce Th1 immune responses. T. cruzi infected rats treated with Lycopodium clavatum extract have reduced progression of GI tract Chagas disease ( Brustolin Aleixo et al, 2017 ). A recent study by Otta et al (2018) showed that K777 the extract lead compound induces prominent proinflammatory responses modulation by interleukin -10-positive CD4 + /CD8 + T cells and this contributed to the protection against the Chagas disease.…”

Section: Host-targeted Therapeutics and Approaches For Treatment Of Cmentioning

confidence: 99%

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

et al. 2018

View full text Add to dashboard Cite

The neglected tropical diseases (NTDs) caused by protozoan parasites are responsible for significant morbidity and mortality worldwide. Current treatments using anti-parasitic drugs are toxic and prolonged with poor patient compliance. In addition, emergence of drug-resistant parasites is increasing worldwide. Hence, there is a need for safer and better therapeutics for these infections. Host-directed therapy using drugs that target host pathways required for pathogen survival or its clearance is a promising approach for treating infections. This review will give a summary of the current status and advances of host-targeted therapies for treating NTDs caused by protozoa.

show abstract

“…LC treatment also induced hypertrophy in neurons present in the distal and proximal colon 125-day postinfection, but after 322 days of infection, this effect was observed only in the distal colon. Thus, an increase in the body area, cytoplasm, and nucleus of neurons was reported when compared to the untreated group [ 20 ].…”

Section: Resultsmentioning

confidence: 99%

Neuroprotective Treatments for Digestive Forms of Chagas Disease in Experimental Models: A Systematic Review

Neto

Guerra

Rodrigues

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Chagas disease is an anthropozoonosis caused by the protozoan Trypanosoma cruzi and is characterized as a neglected disease. It is currently endemic in 21 countries on the Latin American continent, including Bolivia, Argentina, and Paraguay. Unfortunately, there are no optimally effective treatments that can reduce the damage caused in the digestive form of the disease, such as the neuronal destruction of the myenteric plexus of both the esophagus and the colon. Therefore, the objective of this systematic review was to report the possible pharmacological neuroprotective agents that were tested in murine models of the digestive form of Chagas disease. Inclusion criteria are in vivo experimental studies that used different murine models for digestive forms of Chagas disease related to pharmacological interventions with neuroprotective potential, without year and language restriction. On the other hand, the exclusion criteria were studies that did not approach murine models with the digestive form of the disease or did not use neuroprotective treatments, among others. The search in the PubMed, Web of Science, Embase, and LILACS databases was performed on September 4, 2021. In addition, a manual search was performed using the references of the included articles. The risk of bias assessment of the studies was performed based on the SYRCLE tool guidelines, and the data from the selected articles are presented in this review as a narrative description and in tables. Eight articles were included, 4 of which addressed treatment with acetylsalicylic acid, 3 with cyclophosphamide, and 1 with Lycopodium clavatum 13c. In view of the results of the studies, most of them show neuroprotective activity of the treatments, with the potential to reduce the number of damaged neurons, as well as positive changes in the structure of these cells. However, more studies are needed to understand the mechanisms triggered by each drug, as well as their safety and immunogenicity. Systematic review registration is as follows: PROSPERO database (CRD42022289746).

show abstract

Beneficial immunomodulatory and neuro digestive effect in Trypanosoma cruzi infection after Lycopodium clavatum 13c treatment

Cited by 11 publications

References 9 publications

Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson’s Disease

Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson’s Disease

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

Neuroprotective Treatments for Digestive Forms of Chagas Disease in Experimental Models: A Systematic Review

Contact Info

Product

Resources

About